Gender differences in the age-stratified prevalence of risk factors in Korean ischemic stroke patients: a nationwide stroke registry-based cross-sectional study

Authors


  • Conflict of interest:
  • K-H. Y. is involved as a member of steering committee, and/or a site investigator of multicenter clinical trials or clinical studies sponsored by Otsuka Korea, Daewoong Pharmaceutical Co. Ltd, Daichi Sankyo, Novatis Korea, and Pfizer; served as the consultant or scientific advisory boardfor BMS Korea; and received lecture honoraria from MSD Korea, AstraZeneca Korea, BMS Korea, Ostuka Korea, Pfizer Korea, and Daichi Sankyo Korea (modest).
  • P. B. G serves on the Steering Committee for the Bayer-sponsored ARRIVE trial, as co-Director of the Lundbeck-sponsored DIAS trial of desmoteplase in acute ischemic stroke, as a cardiovascular endpoint adjudicator for studies by Roche/Parexel, Takeda, Quintiles/AstraZenica, Shire and Forest Laboratories. Dr Gorelick serves on a speaker's bureau for BoehringerIngelheim in relation to oral anticoagulation in recurrent stroke prevention for atrial fibrillation.
  • H-J. B. is involved in the principal investigator, a member of steering committee, and/or a site investigator of multicenter clinical trials or clinical studies sponsored by Otsuka Korea, Bayer Korea, HandokPahrmaceutical Company, SK Chemicals, ESAI-Korea, Daewoong Pharmaceutical Co. Ltd, Daichi Sankyo, Pfizer, Sanofi-Aventis Korea, and Yuhan Corporation; served as the consultant or scientific advisory board for Bayer Korea, BoehringerIngelheim Korea, YuYu Pharmaceutical Company, and BMS Korea; and received lecture honoraria from MSD Korea, AstraZeneca Korea, BMS Korea, Novatis Korea, Ostuka Korea, Pfizer Korea, Daichi Sankyo Korea, and Handok Pharmaceutical Company (modest).
  • T. H. P, Y. K, S. L., K. B. L., J. L., M-K. H., D-E. K., J.-M.P, Y-J. C., K-S. H., J-T. K., K-H. C., D-H. K., J-K. C., B-C. L., B-W. Y., J. S. L., and J. L. have none.
  • Funding: Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).

Abstract

Background

Although ethnic or cultural differences affect prevalence of cardiovascular risk factors, limited information is available about the age- and gender-stratified prevalence of the risk factors in Asian stroke population.

Aims and hypothesis

We assessed gender- and age-stratified prevalences of major risk factors in Korean stroke patients, and assumed that the gender differences are attenuated by adjustment with lifestyle factors.

Methods

Using the nationwide hospital-based stroke registry, we identified 9417 ischemic stroke patients admitted between April 2008 and January 2011. Prevalence of hypertension, diabetes, hyperlipidemia, atrial fibrillation, prior stroke, and coronary heart disease was assessed in both genders by age groups. We analyzed gender differences of the prevalence among the age groups by calculating prevalence ratio, and further explored the influence of lifestyle factors on the gender difference in multivariable analyses.

Results

Hypertension and hyperlipidemia were more common in men until middle age, but after that more common in women, whereas diabetes was more common in women after 65 years of age. Atrial fibrillation increased steadily with age in both genders but was more common in women through all age groups. Prior stroke and coronary heart disease showed inconsistent gender differences. Gender differences in hypertension and diabetes among the age groups were attenuated by adjustment with accompanying risk factors including lifestyle factors.

Conclusion

Korean women with stroke had more hypertension and hyperlipidemia after middle age, more diabetes after 65 years, and more atrial fibrillation throughout all ages. Strategies to control risk factors in women at risk for stroke are eagerly needed.

Ancillary